Login Register Cart 0
Generic placeholder image

Current Pharmaceutical Biotechnology

Editor-in-Chief

ISSN (Print): 1389-2010
ISSN (Online): 1873-4316

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Review Article

Systematic Review on Herbal Preparations for Controlling Visceral Hypersensitivity in Functional Gastrointestinal Disorders

Author(s): Naser-Aldin Lashgari, Nazanin Momeni Roudsari, Saeideh Momtaz, Faezeh Niazi Shahraki, Nadia Zandi, Benyamin Pazoki, Mohammad Hosein Farzaei*, Mehdi Ghasemi, Mohammad Abdollahi and Amir Hossein Abdolghaffari*

Volume 25, Issue 13, 2024

Published on: 22 January, 2024

Page: [1632 - 1650] Pages: 19

DOI: 10.2174/0113892010261502231102040149

Price: $65

Abstract

Background: Visceral hypersensitivity (VH) is an overreaction of the gastrointestinal (GI) tract to various stimuli and is characterized by hyperalgesia and/or allodynia. VH contributes to the etiology of many GI dysfunctions, particularly irritable bowel syndrome (IBS). Although the exact mechanisms underlying VH are yet to be found, inflammation and oxidative stress, psychosocial factors, and sensorimotor alterations may play significant roles in it.

Objective: In this review, we provide an overview of VH and its pathophysiological function in GI disorders. Adverse effects of synthetic drugs may make herbal agents a good candidate for pain management. Therefore, in this review, we will discuss the efficacy of herbal agents in the management of VH with a focus on their anti-inflammatory and antioxidant potentials.

Methods: Data were extracted from clinical and animal studies published in English between 2004 and June, 2020, which were collected from PubMed, Google Scholar, Scopus, and Cochrane Library.

Results: Overall, Radix, Melissia, Glycyrrhizae, Mentha, and Liquorice were the most efficient herbals for VH management in IBS and dyspepsia, predominantly through modulation of the mRNA expression of transient receptor potential vanilloid type-1 (TRPV1) and suppression of 5- hydroxytryptamine 3 (5-HT3) or the serotonin receptors.

Conclusion: Considering the positive effects of herbal formulations in VH management, further research on novel herbal and/or herbal/chemical preparations is warranted.

« Previous Next »
Graphical Abstract

[1]
Farzaei, M.H.; Bahramsoltani, R.; Abdollahi, M.; Rahimi, R. The role of visceral hypersensitivity in irritable bowel syndrome: pharmacological targets and novel treatments. J. Neurogastroenterol. Motil., 2016, 22(4), 558-574.
[http://dx.doi.org/10.5056/jnm16001] [PMID: 27431236]
[2]
Greenwood-van meerveld, Importance of 5-hydroxytryptamine receptors on intestinal afferents in the regulation of visceral sensitivity. Neurogastroenterol. Motil., 2007, 19(s2)(Suppl. 2), 13-18.
[http://dx.doi.org/10.1111/j.1365-2982.2007.00964.x] [PMID: 17620083]
[3]
Yam, M.; Loh, Y.; Tan, C.; Khadijah Adam, S.; Abdul Manan, N.; Basir, R. General pathways of pain sensation and the major neurotransmitters involved in pain regulation. Int. J. Mol. Sci., 2018, 19(8), 2164.
[http://dx.doi.org/10.3390/ijms19082164] [PMID: 30042373]
[4]
Feng, B.; La, J.H.; Schwartz, E.S.; Gebhart, G.F. Irritable Bowel Syndrome: Methods, Mechanisms, and Pathophysiology. Neural and neuro-immune mechanisms of visceral hypersensitivity in irritable bowel syndrome. Am. J. Physiol. Gastrointest. Liver Physiol., 2012, 302(10), G1085-G1098.
[http://dx.doi.org/10.1152/ajpgi.00542.2011] [PMID: 22403791]
[5]
Akhtar, M.S.; Aslam, M. Anthelmintic efficacies of total alkaloids and glycosides isolated from Punica granatum fruit-rind (anar); Pakistan J. Agricul. Sci, 1988.
[6]
Liu, S.; Hagiwara, S.I.; Bhargava, A. Early‐life adversity, epigenetics, and visceral hypersensitivity. Neurogastroenterol. Motil., 2017, 29(9), e13170.
[http://dx.doi.org/10.1111/nmo.13170] [PMID: 28782197]
[7]
Holzer, P.; Farzi, A.; Hassan, A.M.; Zenz, G.; Jačan, A.; Reichmann, F. Visceral inflammation and immune activation stress the brain. Front. Immunol., 2017, 8, 1613.
[http://dx.doi.org/10.3389/fimmu.2017.01613] [PMID: 29213271]
[8]
Deiteren A.; de Wit, A.; van der Linden, L.; De Man, JG.; Pelckmans, P.A.; De Winter BY Irritable bowel syndrome and visceral hypersensitivity: risk factors and pathophysiological mechanisms. Acta Gastroenterol. Belg., 2016, 79(1), 29-38.
[9]
Zhou, Q.; Verne, G.N. New insights into visceral hypersensitivity—clinical implications in IBS. Nat. Rev. Gastroenterol. Hepatol., 2011, 8(6), 349-355.
[http://dx.doi.org/10.1038/nrgastro.2011.83] [PMID: 21643039]
[10]
Rexwinkel, R.; Zeevenhooven, J.; van Etten-Jamaludin, F.S.; Benninga, M.A.; Tabbers, M.M. Side effects associated with pharmacotherapy for pediatric irritable bowel syndrome and functional abdominal pain – not otherwise specified: a systematic review. Expert Opin. Drug Saf., 2019, 18(2), 111-125.
[http://dx.doi.org/10.1080/14740338.2019.1574295] [PMID: 30676113]
[11]
Domagała-Rodacka, R.; Cibor, D.; Szczeklik, K.; Rodacki, T.; Mach, T.; Owczarek, D. Gastrointestinal tract as a side-effect target of medications. Przegl. Lek., 2016, 73(9), 652-658.
[PMID: 29688675]
[12]
Nyambe, M.; Koekemoer, T.; van de Venter, M.; Goosen, E.; Beukes, D. In vitro evaluation of the phytopharmacological potential of Sargassum incisifolium for the treatment of inflammatory bowel diseases. Medicines (Basel), 2019, 6(2), 49.
[http://dx.doi.org/10.3390/medicines6020049] [PMID: 30959861]
[13]
Qu, L.; Liu, Q.; Zhang, Q.; Tuo, X.; Fan, D.; Deng, J.; Yang, H. Kiwifruit seed oil prevents obesity by regulating inflammation, thermogenesis, and gut microbiota in high-fat diet-induced obese C57BL/6 mice. Food Chem. Toxicol., 2019, 125, 85-94.
[http://dx.doi.org/10.1016/j.fct.2018.12.046] [PMID: 30597221]
[14]
Cavalcante Silva, J; Grasseli, E; Canesi, L; Palombo, D; Abdalla, D. P310 A new dual-PPAR agonist (GQ-11), prevents ischemiareperfusion damage in rats after supraceliac aorta clamping. Eur Heart J-Cardiovas Imag, 2019, 20(Supplement_3), jez148.038.
[15]
Stine, R.R.; Sakers, A.P.; TeSlaa, T.; Kissig, M.; Stine, Z.E.; Kwon, C.W.; Cheng, L.; Lim, H.W.; Kaestner, K.H.; Rabinowitz, J.D.; Seale, P. PRDM16 maintains homeostasis of the intestinal epithelium by controlling region-specific metabolism. Cell Stem Cell, 2019, 25(6), 830-845.e8.
[http://dx.doi.org/10.1016/j.stem.2019.08.017] [PMID: 31564549]
[16]
Delvaux, M. Role of visceral sensitivity in the pathophysiology of irritable bowel syndrome. Gut, 2002, 51(Suppl 1)(Suppl. 1), i67-i71.
[http://dx.doi.org/10.1136/gut.51.suppl_1.i67] [PMID: 12077070]
[17]
Hockley, J.R.F.; Boundouki, G.; Cibert-Goton, V.; McGuire, C.; Yip, P.K.; Chan, C.; Tranter, M.; Wood, J.N.; Nassar, M.A.; Blackshaw, A.L.; Aziz, Q.; Michael, G.J.; Baker, M.D.; Winchester, W.J.; Knowles, C.H.; Bulmer, D.C. Multiple roles for NaV1.9 in the activation of visceral afferents by noxious inflammatory, mechanical, and human disease–derived stimuli. Pain, 2014, 155(10), 1962-1975.
[http://dx.doi.org/10.1016/j.pain.2014.06.015] [PMID: 24972070]
[18]
Kanazawa, M.; Hongo, M.; Fukudo, S. Visceral hypersensitivity in irritable bowel syndrome. J. Gastroenterol. Hepatol., 2011, 26(s3)(Suppl. 3), 119-121.
[http://dx.doi.org/10.1111/j.1440-1746.2011.06640.x] [PMID: 21443723]
[19]
Sarnelli, G.; Vandenberghe, J.; Tack, J. Visceral hypersensitivity in functional disorders of the upper gastrointestinal tract. Dig. Liver Dis., 2004, 36(6), 371-376.
[http://dx.doi.org/10.1016/S1590-8658(04)00082-9] [PMID: 15248374]
[20]
Schumacher, M.A. Transient receptor potential channels in pain and inflammation: therapeutic opportunities. Pain Pract., 2010, 10(3), 185-200.
[http://dx.doi.org/10.1111/j.1533-2500.2010.00358.x] [PMID: 20230457]
[21]
Farmer, A.D.; Aziz, Q. Gut pain & visceral hypersensitivity. Br. J. Pain, 2013, 7(1), 39-47.
[http://dx.doi.org/10.1177/2049463713479229] [PMID: 26516496]
[22]
Keohane, J.; Quigley, E.M.M. Functional dyspepsia: The role of visceral hypersensitivity in its pathogenesis. World J. Gastroenterol., 2006, 12(17), 2672-2676.
[http://dx.doi.org/10.3748/wjg.v12.i17.2672] [PMID: 16718751]
[23]
Keszthelyi, D.; Troost, F.J.; Masclee, A.A. Irritable Bowel Syndrome: Methods, Mechanisms, and Pathophysiology. Methods to assess visceral hypersensitivity in irritable bowel syndrome. Am. J. Physiol. Gastrointest. Liver Physiol., 2012, 303(2), G141-G154.
[http://dx.doi.org/10.1152/ajpgi.00060.2012] [PMID: 22595988]
[24]
Spiller, R.; Lam, C. The shifting interface between IBS and IBD. Curr. Opin. Pharmacol., 2011, 11(6), 586-592.
[http://dx.doi.org/10.1016/j.coph.2011.09.009] [PMID: 22000604]
[25]
Villani, A.C.; Lemire, M.; Thabane, M.; Belisle, A.; Geneau, G.; Garg, A.X.; Clark, W.F.; Moayyedi, P.; Collins, S.M.; Franchimont, D.; Marshall, J.K. Genetic risk factors for post-infectious irritable bowel syndrome following a waterborne outbreak of gastroenteritis. Gastroenterology, 2010, 138(4), 1502-1513.
[http://dx.doi.org/10.1053/j.gastro.2009.12.049] [PMID: 20044998]
[26]
Klooker, T.K.; Braak, B.; Koopman, K.E.; Welting, O.; Wouters, M.M.; van der Heide, S.; Schemann, M.; Bischoff, S.C.; van den Wijngaard, R.M.; Boeckxstaens, G.E. The mast cell stabiliser ketotifen decreases visceral hypersensitivity and improves intestinal symptoms in patients with irritable bowel syndrome. Gut, 2010, 59(9), 1213-1221.
[http://dx.doi.org/10.1136/gut.2010.213108] [PMID: 20650926]
[27]
Tsang, S.W.; Zhao, M.; Wu, J.; Sung, J.J.Y.; Bian, Z.X. Nerve growth factor‐mediated neuronal plasticity in spinal cord contributes to neonatal maternal separation‐induced visceral hypersensitivity in rats. Eur. J. Pain, 2012, 16(4), 463-472.
[http://dx.doi.org/10.1016/j.ejpain.2011.07.005] [PMID: 22396076]
[28]
Russo, E.B. Clinical endocannabinoid deficiency reconsidered: current research supports the theory in migraine, fibromyalgia, irritable bowel, and other treatment-resistant syndromes. Cannabis Cannabinoid Res., 2016, 1(1), 154-165.
[http://dx.doi.org/10.1089/can.2016.0009] [PMID: 28861491]
[29]
Mawe, G.M.; Coates, M.D.; Moses, P.L. Review article: intestinal serotonin signalling in irritable bowel syndrome. Aliment. Pharmacol. Ther., 2006, 23(8), 1067-1076.
[http://dx.doi.org/10.1111/j.1365-2036.2006.02858.x] [PMID: 16611266]
[30]
Kim, J.J.; Kim, N.; Choi, Y.J.; Kim, J.S.; Jung, H.C. Increased TRPV1 and PAR2 mRNA expression levels are associated only with the esophageal reflux symptoms, but not with the extraesophageal reflux symptoms. Medicine (Baltimore), 2016, 95(32), e4387.
[http://dx.doi.org/10.1097/MD.0000000000004387] [PMID: 27512850]
[31]
Yoshida, N.; Kuroda, M.; Suzuki, T.; Kamada, K.; Uchiyama, K.; Handa, O.; Takagi, T.; Yoshikawa, T.; Kuramoto, H. Role of nociceptors/neuropeptides in the pathogenesis of visceral hypersensitivity of nonerosive reflux disease. Dig. Dis. Sci., 2013, 58(8), 2237-2243.
[http://dx.doi.org/10.1007/s10620-012-2337-7] [PMID: 22899239]
[32]
Sarkar, S.; Hobson, A.R.; Furlong, P.L.; Woolf, C.J.; Thompson, D.G.; Aziz, Q. Central neural mechanisms mediating human visceral hypersensitivity. Am. J. Physiol. Gastrointest. Liver Physiol., 2001, 281(5), G1196-G1202.
[http://dx.doi.org/10.1152/ajpgi.2001.281.5.G1196] [PMID: 11668028]
[33]
Tack, J.; Vanuytsel, T.; Pauwels, A. Established and emerging treatment options for functional heartburn and chest pain. Curr. Treat. Options Gastroenterol., 2016, 14(1), 19-27.
[http://dx.doi.org/10.1007/s11938-016-0081-3] [PMID: 26825704]
[34]
Van Handel, D.; Fass, R. The pathophysiology of non-cardiac chest pain. J. Gastroenterol. Hepatol., 2005, 20(s3)(Suppl.), S6-S13.
[http://dx.doi.org/10.1111/j.1440-1746.2005.04165.x] [PMID: 16359347]
[35]
Lee, J.Y.; Kim, N.; Park, J.H.; Nam, R.H.; Lee, S.M.; Song, C.H.; Kim, G.; Na, H.Y.; Choi, Y.J.; Kim, J.J.; Lee, D.H. Expression of neurotrophic factors, tight junction proteins, and cytokines according to the irritable bowel syndrome subtype and sex. J. Neurogastroenterol. Motil., 2020, 26(1), 106-116.
[http://dx.doi.org/10.5056/jnm19099] [PMID: 31623029]
[36]
Naveed, M.; Hejazi, V.; Abbas, M.; Kamboh, A.A.; Khan, G.J.; Shumzaid, M.; Ahmad, F.; Babazadeh, D. FangFang, X.; Modarresi-Ghazani, F.; WenHua, L.; XiaoHui, Z. Chlorogenic acid (CGA): A pharmacological review and call for further research. Biomed. Pharmacother., 2018, 97, 67-74.
[http://dx.doi.org/10.1016/j.biopha.2017.10.064] [PMID: 29080460]
[37]
Sikandar, S.; Dickenson, A.H. Visceral pain. Curr. Opin. Support. Palliat. Care, 2012, 6(1), 17-26.
[http://dx.doi.org/10.1097/SPC.0b013e32834f6ec9] [PMID: 22246042]
[38]
Fukudo, S.; Kuwano, H.; Miwa, H. Management and pathophysiology of functional gastrointestinal disorders. Digestion, 2012, 85(2), 85-89.
[http://dx.doi.org/10.1159/000334652] [PMID: 22269284]
[39]
Ritchie, J. Pain from distension of the pelvic colon by inflating a balloon in the irritable colon syndrome. Gut, 1973, 14(2), 125-132.
[http://dx.doi.org/10.1136/gut.14.2.125] [PMID: 4696535]
[40]
Taki, M.; Oshima, T.; Li, M.; Sei, H.; Tozawa, K.; Tomita, T.; Fukui, H.; Watari, J.; Miwa, H. Duodenal low‐grade inflammation and expression of tight junction proteins in functional dyspepsia. Neurogastroenterol. Motil., 2019, 31(10), e13576.
[http://dx.doi.org/10.1111/nmo.13576] [PMID: 30790378]
[41]
Cremon, C.; Carini, G.; Wang, B.; Vasina, V.; Cogliandro, R.F.; De Giorgio, R.; Stanghellini, V.; Grundy, D.; Tonini, M.; De Ponti, F.; Corinaldesi, R.; Barbara, G. Intestinal serotonin release, sensory neuron activation, and abdominal pain in irritable bowel syndrome. Am. J. Gastroenterol., 2011, 106(7), 1290-1298.
[http://dx.doi.org/10.1038/ajg.2011.86] [PMID: 21427712]
[42]
Barbara, G.; Cremon, C.; De Giorgio, R.; Dothel, G.; Zecchi, L.; Bellacosa, L.; Carini, G.; Stanghellini, V.; Corinaldesi, R. Mechanisms underlying visceral hypersensitivity in irritable bowel syndrome. Curr. Gastroenterol. Rep., 2011, 13(4), 308-315.
[http://dx.doi.org/10.1007/s11894-011-0195-7] [PMID: 21537962]
[43]
Akbar, A.; Walters, J.R.F.; Ghosh, S. Review article: visceral hypersensitivity in irritable bowel syndrome: Molecular mechanisms and therapeutic agents. Aliment. Pharmacol. Ther., 2009, 30(5), 423-435.
[http://dx.doi.org/10.1111/j.1365-2036.2009.04056.x] [PMID: 19493256]
[44]
Lee, K.N.; Lee, O.Y. Intestinal microbiota in pathophysiology and management of irritable bowel syndrome. World J. Gastroenterol., 2014, 20(27), 8886-8897.
[PMID: 25083061]
[45]
Ceuleers, H.; Van Spaendonk, H.; Hanning, N.; Heirbaut, J.; Lambeir, A.M.; Joossens, J.; Augustyns, K.; De Man, J.G.; De Meester, I.; De Winter, B.Y. Visceral hypersensitivity in inflammatory bowel diseases and irritable bowel syndrome: The role of proteases. World J. Gastroenterol., 2016, 22(47), 10275-10286.
[http://dx.doi.org/10.3748/wjg.v22.i47.10275] [PMID: 28058009]
[46]
Lackner, J.M.; Gudleski, G.D.; Thakur, E.R.; Stewart, T.J.; Iacobucci, G.J.; Spiegel, B.M.R. The impact of physical complaints, social environment, and psychological functioning on IBS patients’ health perceptions: looking beyond GI symptom severity. Am. J. Gastroenterol., 2014, 109(2), 224-233.
[http://dx.doi.org/10.1038/ajg.2013.410] [PMID: 24419481]
[47]
Pradhan, K.; Thakur, D.; Sudhan, N. Therapeutic efficacy of Punica granatum and Cucurbita maxima against clinical cases of nematodiasis in calves. Indian J. Indigenous Med, 1993.
[48]
Carroll, S.Y.; O’Mahony, S.M.; Grenham, S.; Cryan, J.F.; Hyland, N.P. Disodium cromoglycate reverses colonic visceral hypersensitivity and influences colonic ion transport in a stress-sensitive rat strain. PLoS One, 2013, 8(12), e84718.
[http://dx.doi.org/10.1371/journal.pone.0084718] [PMID: 24367692]
[49]
Camilleri, M.; Boeckxstaens, G. Dietary and pharmacological treatment of abdominal pain in IBS. Gut, 2017, 66(5), 966-974.
[http://dx.doi.org/10.1136/gutjnl-2016-313425] [PMID: 28232472]
[50]
Camilleri, M.; Ford, A. Pharmacotherapy for irritable bowel syndrome. J. Clin. Med., 2017, 6(11), 101.
[http://dx.doi.org/10.3390/jcm6110101] [PMID: 29077050]
[51]
Nelson, A.D.; Camilleri, M.; Chirapongsathorn, S.; Vijayvargiya, P.; Valentin, N.; Shin, A.; Erwin, P.J.; Wang, Z.; Murad, M.H. Comparison of efficacy of pharmacological treatments for chronic idiopathic constipation: a systematic review and network meta-analysis. Gut, 2017, 66(9), 1611-1622.
[http://dx.doi.org/10.1136/gutjnl-2016-311835] [PMID: 27287486]
[52]
Stanisor, O.I.; van Diest, S.A.; Yu, Z.; Welting, O.; Bekkali, N.; Shi, J.; de Jonge, W.J.; Boeckxstaens, G.E.; van den Wijngaard, R.M. Stress-induced visceral hypersensitivity in maternally separated rats can be reversed by peripherally restricted histamine-1-receptor antagonists. PLoS One, 2013, 8(6), e66884.
[http://dx.doi.org/10.1371/journal.pone.0066884] [PMID: 23776699]
[53]
Riediger, C.; Schuster, T.; Barlinn, K.; Maier, S.; Weitz, J.; Siepmann, T. Adverse effects of antidepressants for chronic pain: A systematic review and meta-analysis. Front. Neurol., 2017, 8(307), 307.
[http://dx.doi.org/10.3389/fneur.2017.00307] [PMID: 28769859]
[54]
Balemans, D.; Boeckxstaens, G.E.; Talavera, K.; Wouters, M.M. Transient receptor potential ion channel function in sensory transduction and cellular signaling cascades underlying visceral hypersensitivity. Am. J. Physiol. Gastrointest. Liver Physiol., 2017, 312(6), G635-G648.
[http://dx.doi.org/10.1152/ajpgi.00401.2016] [PMID: 28385695]
[55]
Chan, C.L.H.; Facer, P.; Davis, J.B.; Smith, G.D.; Egerton, J.; Bountra, C.; Williams, N.S.; Anand, P. Sensory fibres expressing capsaicin receptor TRPV1 in patients with rectal hypersensitivity and faecal urgency. Lancet, 2003, 361(9355), 385-391.
[http://dx.doi.org/10.1016/S0140-6736(03)12392-6] [PMID: 12573376]
[56]
Chen, L.; Ilham, S.J.; Feng, B. Pharmacological approach for managing pain in irritable bowel syndrome: a review article. Anesth. Pain Med., 2017, 7(2), e42747.
[http://dx.doi.org/10.5812/aapm.42747] [PMID: 28824858]
[57]
Annaházi, A.; Róka, R.; Rosztóczy, A.; Wittmann, T. Role of antispasmodics in the treatment of irritable bowel syndrome. World J. Gastroenterol., 2014, 20(20), 6031-6043.
[http://dx.doi.org/10.3748/wjg.v20.i20.6031] [PMID: 24876726]
[58]
Fuentes, I.M.; Christianson, J.A. Ion channels, ion channel receptors, and visceral hypersensitivity in irritable bowel syndrome. Neurogastroenterol. Motil., 2016, 28(11), 1613-1618.
[http://dx.doi.org/10.1111/nmo.12979] [PMID: 27781369]
[59]
Winston, JH.; Xu, GY.; Sarna, SK. Adrenergic stimulation mediates visceral hypersensitivity to colorectal distension following heterotypic chronic stress. Gastroenterology, 2010, 138(1), 294-304.
[http://dx.doi.org/10.1053/j.gastro.2009.09.054]
[60]
Iwata, Y.; Ando, K.; Taniguchi, K.; Koba, N.; Sugiura, A.; Sudo, M. Identification of a highly potent and selective CB2 agonist, RQ-00202730, for the treatment of irritable bowel syndrome. Bioorg. Med. Chem. Lett., 2015, 25(2), 236-240.
[http://dx.doi.org/10.1016/j.bmcl.2014.11.062] [PMID: 25499880]
[61]
Kikuchi, A.; Ohashi, K.; Sugie, Y.; Sugimoto, H.; Omura, H. Pharmacological evaluation of a novel cannabinoid 2 (CB2) ligand, PF-03550096, in vitro and in vivo by using a rat model of visceral hypersensitivity. J. Pharmacol. Sci., 2008, 106(2), 219-224.
[http://dx.doi.org/10.1254/jphs.FP0071599] [PMID: 18270474]
[62]
Castro, J.; Harrington, AM.; Hughes, PA.; Martin, CM.; Ge, P.; Shea, CM. Linaclotide inhibits colonic nociceptors and relieves abdominal pain via guanylate cyclase-C and extracellular cyclic guanosine 3′, 5′-monophosphate. Gastroenterology, 2013, 145(6), 1334-1346.
[63]
Zong, Y.; Zhu, S.; Zhang, S.; Zheng, G.; Wiley, J.W.; Hong, S. Chronic stress and intestinal permeability: Lubiprostone regulates glucocorticoid receptor‐mediated changes in colon epithelial tight junction proteins, barrier function, and visceral pain in the rodent and human. Neurogastroenterol. Motil., 2019, 31(2), e13477.
[http://dx.doi.org/10.1111/nmo.13477] [PMID: 30284340]
[64]
Roudsari, N.M.; Lashgari, N.A.; Momtaz, S.; Farzaei, M.H.; Marques, A.M.; Abdolghaffari, A.H. Natural polyphenols for the prevention of irritable bowel syndrome: molecular mechanisms and targets; a comprehensive review. Daru, 2019, 27(2), 755-780.
[http://dx.doi.org/10.1007/s40199-019-00284-1] [PMID: 31273572]
[65]
Tan, N.; Gwee, K.A.; Tack, J.; Zhang, M.; Li, Y.; Chen, M.; Xiao, Y. Herbal medicine in the treatment of functional gastrointestinal disorders: A systematic review with meta‐analysis. J. Gastroenterol. Hepatol., 2020, 35(4), 544-556.
[http://dx.doi.org/10.1111/jgh.14905] [PMID: 31674057]
[66]
Hawrelak, J.A.; Wohlmuth, H.; Pattinson, M.; Myers, S.P.; Goldenberg, J.Z.; Harnett, J.; Cooley, K.; Van De Venter, C.; Reid, R.; Whitten, D.L. Western herbal medicines in the treatment of irritable bowel syndrome: A systematic review and meta-analysis. Complement. Ther. Med., 2020, 48, 102233.
[http://dx.doi.org/10.1016/j.ctim.2019.102233] [PMID: 31987249]
[67]
Vandenberghe, A.; Schol, J.; Van den Houte, K.; Masuy, I.; Carbone, F.; Tack, J. Current and emerging therapeutic options for the management of functional dyspepsia. Expert Opin. Pharmacother., 2020, 21(3), 365-376.
[http://dx.doi.org/10.1080/14656566.2019.1707805] [PMID: 31899982]
[68]
Pountos, I.; Theodora Georgouli, ; Howard Bird, ; Giannoudis, P. Nonsteroidal anti-inflammatory drugs: prostaglandins, indications, and side effects. Int. J. Infereron Cytokine Mediator Res., 2011, 3, 19.
[http://dx.doi.org/10.2147/IJICMR.S10200]
[69]
Lazzaroni, M.; Bianchi Porro, G. Gastrointestinal side-effects of traditional non-steroidal anti-inflammatory drugs and new formulations. Aliment. Pharmacol. Ther., 2004, 20(Suppl. 2), 48-58.
[http://dx.doi.org/10.1111/j.1365-2036.2004.02037.x] [PMID: 15335413]
[70]
Sostres, C.; Gargallo, C.J.; Lanas, A. Nonsteroidal anti-inflammatory drugs and upper and lower gastrointestinal mucosal damage. Arthritis Res. Ther., 2013, 15(Suppl 3)(Suppl. 3), S3.
[http://dx.doi.org/10.1186/ar4175] [PMID: 24267289]
[71]
Dolatabadi, F.; Abdolghaffari, A.H.; Farzaei, M.H.; Baeeri, M.; Ziarani, F.S.; Eslami, M.; Abdollahi, M.; Rahimi, R. The protective effect of melissa officinalis l. in visceral hypersensitivity in rat using 2 models of acid-induced colitis and stress-induced irritable bowel syndrome: A possible role of nitric oxide pathway. J. Neurogastroenterol. Motil., 2018, 24(3), 490-501.
[http://dx.doi.org/10.5056/jnm17035] [PMID: 29879761]
[72]
Ribeiro, M.A.; Bernardo-Gil, M.G.; Esquível, M.M. Melissa officinalis, L.: study of antioxidant activity in supercritical residues. J. Supercrit. Fluids, 2001, 21(1), 51-60.
[http://dx.doi.org/10.1016/S0896-8446(01)00078-X]
[73]
Miraj, S.; Azizi, N.; Kiani, S. A review of chemical components and pharmacological effects of Melissa officinalis L. Pharm. Lett., 2016, 8(6), 229-237.
[74]
Noguchi-Shinohara, M.; Ono, K.; Hamaguchi, T.; Iwasa, K.; Nagai, T.; Kobayashi, S.; Nakamura, H.; Yamada, M. Pharmacokinetics, safety and tolerability of melissa officinalis extract which contained rosmarinic acid in healthy individuals: A randomized controlled trial. PLoS One, 2015, 10(5), e0126422.
[http://dx.doi.org/10.1371/journal.pone.0126422] [PMID: 25978046]
[75]
Alijaniha, F.; Naseri, M.; Afsharypuor, S.; Fallahi, F.; Noorbala, A.; Mosaddegh, M.; Faghihzadeh, S.; Sadrai, S. Heart palpitation relief with Melissa officinalis leaf extract: Double blind, randomized, placebo controlled trial of efficacy and safety. J. Ethnopharmacol., 2015, 164, 378-384.
[http://dx.doi.org/10.1016/j.jep.2015.02.007] [PMID: 25680840]
[76]
Akhondzadeh, S.; Noroozian, M.; Mohammadi, M.; Ohadinia, S.; Jamshidi, A.H.; Khani, M. Melissa officinalis extract in the treatment of patients with mild to moderate Alzheimer’s disease: A double blind, randomised, placebo controlled trial. J. Neurol. Neurosurg. Psychiatry, 2003, 74(7), 863-866.
[http://dx.doi.org/10.1136/jnnp.74.7.863] [PMID: 12810768]
[77]
Shakeri, A.; Sahebkar, A.; Javadi, B. Melissa officinalis L. – A review of its traditional uses, phytochemistry and pharmacology. J. Ethnopharmacol., 2016, 188, 204-228.
[http://dx.doi.org/10.1016/j.jep.2016.05.010] [PMID: 27167460]
[78]
Son, H.J.; Jung, K.; Park, Y.H.; Jeon, H.J.; Kang, M.; Ryu, K.H.; Pyo, S.S.; Eutamene, H.; Bueno, L.; Sun, W.S. Inhibitory effects of SKI3246, the rhizome extract of Atractylodes japonica, on visceral hypersensitivity in experimental irritable bowel syndrome rat models. Arch. Pharm. Res., 2015, 38(5), 642-649.
[http://dx.doi.org/10.1007/s12272-014-0454-x] [PMID: 25070763]
[79]
Park, J.J.; Chon, N.R.; Lee, Y.J.; Park, H. The effects of an extract of Atractylodes japonica rhizome, SKI3246 on gastrointestinal motility in guinea pigs. J. Neurogastroenterol. Motil., 2015, 21(3), 352-360.
[http://dx.doi.org/10.5056/jnm14112] [PMID: 26130631]
[80]
Kim, Y.C.; Jun, M.; Jeong, W.S.; Chung, S.K. antioxidant properties of flavone C‐glycosides from atractylodes japonica leaves in human low‐density lipoprotein oxidation. J. Food Sci., 2005, 70(9), S575-S580.
[http://dx.doi.org/10.1111/j.1365-2621.2005.tb08331.x]
[81]
Kim, J.H.; Lee, J.H.; Jeong, S.M.; Lee, B.H.; Yoon, I.S.; Lee, J.H.; Choi, S.H.; Nah, S.Y. Effect of ginseng saponins on a rat visceral hypersensitivity model. Biol. Pharm. Bull., 2005, 28(11), 2120-2124.
[http://dx.doi.org/10.1248/bpb.28.2120] [PMID: 16272701]
[82]
Kim, J.; Nah, S. Effects of ginsenoside total saponins on experimental irritable bowel syndrome in rats. J. Ginseng Res., 2005, 29(2), 94-99.
[http://dx.doi.org/10.5142/JGR.2005.29.2.094]
[83]
Rocha, H.A.C.; Rocha, T.V.; Nóbrega, F.J.F.; Morais, L.C.S.; Diniz, M.F.F.M. Randomized controlled trial of Panax ginseng in patients with irritable bowel syndrome. Rev. Bras. Farmacogn., 2018, 28(2), 218-222.
[http://dx.doi.org/10.1016/j.bjp.2018.02.007]
[84]
Khanna, R.; MacDonald, J.K.; Levesque, B.G. Peppermint oil for the treatment of irritable bowel syndrome: A systematic review and meta-analysis. J. Clin. Gastroenterol., 2014, 48(6), 505-512.
[http://dx.doi.org/10.1097/MCG.0b013e3182a88357] [PMID: 24100754]
[85]
Galeotti, N.; Di Cesare Mannelli, L.; Mazzanti, G.; Bartolini, A.; Ghelardini, C. Menthol: A natural analgesic compound. Neurosci. Lett., 2002, 322(3), 145-148.
[http://dx.doi.org/10.1016/S0304-3940(01)02527-7] [PMID: 11897159]
[86]
Liu, B.; Fan, L.; Balakrishna, S.; Sui, A.; Morris, J.B.; Jordt, S.E. TRPM8 is the principal mediator of menthol-induced analgesia of acute and inflammatory pain. Pain, 2013, 154(10), 2169-2177.
[http://dx.doi.org/10.1016/j.pain.2013.06.043] [PMID: 23820004]
[87]
Harrington, A.M.; Hughes, P.A.; Martin, C.M.; Yang, J.; Castro, J.; Isaacs, N.J.; Blackshaw, A.L.; Brierley, S.M. A novel role for TRPM8 in visceral afferent function. Pain, 2011, 152(7), 1459-1468.
[http://dx.doi.org/10.1016/j.pain.2011.01.027] [PMID: 21489690]
[88]
Rich, G.; Shah, A.; Koloski, N.; Funk, P.; Stracke, B.; Köhler, S.; Holtmann, G. A randomized placebo-controlled trial on the effects of Menthacarin, a proprietary peppermint- and caraway-oil-preparation, on symptoms and quality of life in patients with functional dyspepsia. Neurogastroenterol. Motil., 2017, 29(11), e13132.
[http://dx.doi.org/10.1111/nmo.13132] [PMID: 28695660]
[89]
Botschuijver, S.; Welting, O.; Levin, E.; Maria-Ferreira, D.; Koch, E.; Montijn, R.C.; Seppen, J.; Hakvoort, T.B.M.; Schuren, F.H.J.; de Jonge, W.J.; van den Wijngaard, R.M. Reversal of visceral hypersensitivity in rat by Menthacarin ®, a proprietary combination of essential oils from peppermint and caraway, coincides with mycobiome modulation. Neurogastroenterol. Motil., 2018, 30(6), e13299.
[http://dx.doi.org/10.1111/nmo.13299] [PMID: 29383802]
[90]
Yang, J.M.; Xian, Y.F.; Ip, P.S.P.; Wu, J.C.Y.; Lao, L.; Fong, H.H.S.; Sung, J.J.Y.; Berman, B.; Yeung, J.H.K.; Che, C.T. Schisandra chinensis reverses visceral hypersensitivity in a neonatal–maternal separated rat model. Phytomedicine, 2012, 19(5), 402-408.
[http://dx.doi.org/10.1016/j.phymed.2011.11.013] [PMID: 22230486]
[91]
Amiri, M.; Navabi, J.; Shokoohinia, Y.; Heydarpour, F.; Bahrami, G.; Behbood, L.; Derakhshandeh, P.; Momtaz, S.; Farzaei, M.H. Efficacy and safety of a standardized extract from Achillea wilhelmsii C. Koch in patients with ulcerative colitis: A randomized double blind placebo-controlled clinical trial. Complement. Ther. Med., 2019, 45, 262-268.
[http://dx.doi.org/10.1016/j.ctim.2019.05.001] [PMID: 31331572]
[92]
Lashgari, N.A.; Momeni Roudsari, N.; Khayatan, D.; Shayan, M.; Momtaz, S.; Roufogalis, B.D. Ginger and its constituents: Role in treatment of inflammatory bowel disease. Biofactors, 2021, 48(1), 7-21.
[PMID: 34882874]
[93]
Zhang, C.; Huang, Y.; Li, P.; Chen, X.; Liu, F.; Hou, Q. Ginger relieves intestinal hypersensitivity of diarrhea predominant irritable bowel syndrome by inhibiting proinflammatory reaction. BMC Complement Med Ther., 2020, 20(1), 272.
[http://dx.doi.org/10.1186/s12906-020-03059-3]
[94]
Simrén, M.; Törnblom, H.; Palsson, OS.; Van Oudenhove, L.; Whitehead, WE.; Tack, J. Cumulative effects of psychologic distress, visceral hypersensitivity, and abnormal transit on patient-reported outcomes in irritable bowel syndrome. Gastroenterology, 2019, 157(2), 391-402.
[http://dx.doi.org/10.1053/j.gastro.2019.04.019]
[95]
Shi, H.; Zhu, X.; Cui, Y.; Qin, Y.; Yang, L.; Deng, X. Analgesic activity of cynaropicrinon on post inflammatory irritable bowel syndrome visceral hypersensitivity in a rat model. Exp. Ther. Med., 2017, 14(5), 4476-4482.
[http://dx.doi.org/10.3892/etm.2017.5037] [PMID: 29067122]
[96]
Rahimi, R.; Abdollahi, M. Herbal medicines for the management of irritable bowel syndrome: A comprehensive review. World J. Gastroenterol., 2012, 18(7), 589-600.
[http://dx.doi.org/10.3748/wjg.v18.i7.589] [PMID: 22363129]
[97]
Abdollahi, M.; Esmaily, H.; Baeeri, M.; Asadi-Shahmirzadi, A.; Mozaffari, S.; Rahimi, R.; Sanei, Y.; Salehi-Surmaghi, M-H. Effects of Hypericum perforatum extract on rat irritable bowel syndrome. Pharmacogn. Mag., 2011, 7(27), 213-223.
[http://dx.doi.org/10.4103/0973-1296.84235] [PMID: 21969792]
[98]
Brinkhaus, B.; Hentschel, C.; Keudell, C.V.; Schindler, G.; Lindner, M.; Stützer, H.; Kohnen, R.; Willich, S.N.; Lehmacher, W.; Hahn, E.G.G. Herbal medicine with curcuma and fumitory in the treatment of irritable bowel syndrome: A randomized, placebo-controlled, double-blind clinical trial. Scand. J. Gastroenterol., 2005, 40(8), 936-943.
[http://dx.doi.org/10.1080/00365520510023134] [PMID: 16173134]
[99]
Cooke, C.; Carr, I.; Abrams, K.; Mayberry, J. Arrowroot as a treatment for diarrhoea in irritable bowel syndrome patients: a pilot study. Arq. Gastroenterol., 2000, 37(1), 20-24.
[http://dx.doi.org/10.1590/S0004-28032000000100005] [PMID: 10962623]
[100]
Uezono, Y.; Miyano, K. Visceral hypersensitivity in functional dyspepsia (FD): Therapeutic approaches to FD based on suppression of visceral hypersensitivity. Functional Dyspepsia; Springer: Cham, 2018, pp. 167-177.
[http://dx.doi.org/10.1007/978-981-13-1074-4_15]
[101]
Liu, C.Y.; Müller, M.H.; Glatzle, J.; Weiser, D.; Kelber, O.; Enck, P.; Grundy, D.; Kreis, M.E. The herbal preparation STW 5 (IberogastR) desensitizes intestinal afferents in the rat small intestine1. Neurogastroenterol. Motil., 2004, 16(6), 759-764.
[http://dx.doi.org/10.1111/j.1365-2982.2004.00576.x] [PMID: 15601426]
[102]
Hong, S.W.; Chun, J.; Park, S.; Lee, H.J.; Im, J.P.; Kim, J.S. Aloe vera is effective and safe in short-term treatment of irritable bowel syndrome: a systematic review and meta-analysis. J. Neurogastroenterol. Motil., 2018, 24(4), 528-535.
[http://dx.doi.org/10.5056/jnm18077] [PMID: 30153721]
[103]
Asadi-Shahmirzadi, A.; Mozaffari, S.; Sanei, Y.; Baeeri, M.; Hajiaghaee, R.; Monsef-Esfahani, H.R.; Abdollahi, M. Benefit of Aloe vera and Matricaria recutita mixture in rat irritable bowel syndrome: Combination of antioxidant and spasmolytic effects. Chin. J. Integr. Med., 2012, 1-9.
[http://dx.doi.org/10.1007/s11655-012-1027-9] [PMID: 23263994]
[104]
Davis, K.; Philpott, S.; Kumar, D.; Mendall, M. Randomised double-blind placebo-controlled trial of aloe vera for irritable bowel syndrome. Int. J. Clin. Pract., 2006, 60(9), 1080-1086.
[http://dx.doi.org/10.1111/j.1742-1241.2006.00980.x] [PMID: 16749917]
[105]
Malik, Z.; Baik, D.; Schey, R. The role of cannabinoids in regulation of nausea and vomiting, and visceral pain. Curr. Gastroenterol. Rep., 2015, 17(2), 9.
[http://dx.doi.org/10.1007/s11894-015-0429-1] [PMID: 25715910]
[106]
Bogale, K.; Raup-Konsavage, W.; Dalessio, S.; Vrana, K.; Coates, M.D. Cannabis and cannabis derivatives for abdominal pain management in inflammatory bowel disease. Med. Cannabis Cannabinoids, 2021, 4(2), 97-106.
[http://dx.doi.org/10.1159/000517425] [PMID: 35224429]
[107]
Ng, Q.X.; Koh, S.S.H.; Chan, H.W.; Ho, C.Y.X. Clinical use of curcumin in depression: a meta-analysis. J. Am. Med. Dir. Assoc., 2017, 18(6), 503-508.
[http://dx.doi.org/10.1016/j.jamda.2016.12.071] [PMID: 28236605]
[108]
Aggarwal, B.B.; Harikumar, K.B. Potential therapeutic effects of curcumin, the anti-inflammatory agent, against neurodegenerative, cardiovascular, pulmonary, metabolic, autoimmune and neoplastic diseases. Int. J. Biochem. Cell Biol., 2009, 41(1), 40-59.
[http://dx.doi.org/10.1016/j.biocel.2008.06.010] [PMID: 18662800]
[109]
Ak, T.; Gülçin, İ. Antioxidant and radical scavenging properties of curcumin. Chem. Biol. Interact., 2008, 174(1), 27-37.
[http://dx.doi.org/10.1016/j.cbi.2008.05.003] [PMID: 18547552]
[110]
Dong, S.; Zeng, Q.; Mitchell, E.S.; Xiu, J.; Duan, Y.; Li, C.; Tiwari, J.K.; Hu, Y.; Cao, X.; Zhao, Z. Curcumin enhances neurogenesis and cognition in aged rats: implications for transcriptional interactions related to growth and synaptic plasticity. PLoS One, 2012, 7(2), e31211.
[http://dx.doi.org/10.1371/journal.pone.0031211] [PMID: 22359574]
[111]
Ammon, H.; Wahl, M. Pharmacology of Curcuma longa. Planta Med., 1991, 57(1), 1-7.
[http://dx.doi.org/10.1055/s-2006-960004] [PMID: 2062949]
[112]
Yu, Y.; Wu, S.; Li, J.; Wang, R.; Xie, X.; Yu, X.; Pan, J.; Xu, Y.; Zheng, L. The effect of curcumin on the brain-gut axis in rat model of irritable bowel syndrome: involvement of 5-HT-dependent signaling. Metab. Brain Dis., 2015, 30(1), 47-55.
[http://dx.doi.org/10.1007/s11011-014-9554-z] [PMID: 24807589]
[113]
Zhi, L.; Dong, L.; Kong, D.; Sun, B.; Sun, Q.; Grundy, D.; Zhang, G.; Rong, W. Curcumin acts via transient receptor potential vanilloid-1 receptors to inhibit gut nociception and reverses visceral hyperalgesia. Neurogastroenterol. Motil., 2013, 25(6), e429-e440.
[http://dx.doi.org/10.1111/nmo.12145] [PMID: 23638900]
[114]
Qin, S.; Huang, L.; Gong, J.; Shen, S.; Huang, J.; Ren, H.; Hu, H. Efficacy and safety of turmeric and curcumin in lowering blood lipid levels in patients with cardiovascular risk factors: a meta-analysis of randomized controlled trials. Nutr. J., 2017, 16(1), 68.
[http://dx.doi.org/10.1186/s12937-017-0293-y] [PMID: 29020971]
[115]
Chung, J.H. Metabolic benefits of inhibiting cAMP-PDEs with resveratrol. Adipocyte, 2012, 1(4), 256-258.
[http://dx.doi.org/10.4161/adip.21158] [PMID: 23700542]
[116]
Sale, S.; Verschoyle, R.D.; Boocock, D.; Jones, D.J.L.; Wilsher, N.; Ruparelia, K.C.; Potter, G.A.; Farmer, P.B.; Steward, W.P.; Gescher, A.J. Pharmacokinetics in mice and growth-inhibitory properties of the putative cancer chemopreventive agent resveratrol and the synthetic analogue trans 3,4,5,4′-tetramethoxystilbene. Br. J. Cancer, 2004, 90(3), 736-744.
[http://dx.doi.org/10.1038/sj.bjc.6601568] [PMID: 14760392]
[117]
Frozza, R.L.; Bernardi, A.; Paese, K.; Hoppe, J.B.; Silva, T.; Battastini, A.M.O.; Pohlmann, A.R.; Guterres, S.S.; Salbego, C. Characterization of trans-resveratrol-loaded lipid-core nanocapsules and tissue distribution studies in rats. J. Biomed. Nanotechnol., 2010, 6(6), 694-703.
[http://dx.doi.org/10.1166/jbn.2010.1161] [PMID: 21361135]
[118]
Xu, Y.; Cui, S.Y.; Ma, Q.; Shi, J.; Yu, Y.; Li, J.X.; Zheng, L.; Zhang, Y.; Si, J.M.; Yu, Y.C. Trans-resveratrol ameliorates stress-induced irritable bowel syndrome-like behaviors by regulation of brain-gut axis. Front. Pharmacol., 2018, 9, 631.
[http://dx.doi.org/10.3389/fphar.2018.00631] [PMID: 29962949]
[119]
Lu, Y.; Xu, H.; Han, Y.; Zhang, Y. Analgesic effect of resveratrol on colitis-induced visceral pain via inhibition of TRAF6/NF-κB signaling pathway in the spinal cord. Brain Res., 2019, 1724, 146464.
[http://dx.doi.org/10.1016/j.brainres.2019.146464] [PMID: 31536729]
[120]
Parasuraman, S.; Anand David, A.V.; Arulmoli, R. Overviews of biological importance of quercetin: A bioactive flavonoid. Pharmacogn. Rev., 2016, 10(20), 84-89.
[http://dx.doi.org/10.4103/0973-7847.194044] [PMID: 28082789]
[121]
Espley, R.V.; Butts, C.A.; Laing, W.A.; Martell, S.; Smith, H.; McGhie, T.K.; Zhang, J.; Paturi, G.; Hedderley, D.; Bovy, A.; Schouten, H.J.; Putterill, J.; Allan, A.C.; Hellens, R.P. Dietary flavonoids from modified apple reduce inflammation markers and modulate gut microbiota in mice. J. Nutr., 2014, 144(2), 146-154.
[http://dx.doi.org/10.3945/jn.113.182659] [PMID: 24353343]
[122]
Yano, J.M.; Yu, K.; Donaldson, G.P.; Shastri, G.G.; Ann, P.; Ma, L.; Nagler, C.R.; Ismagilov, R.F.; Mazmanian, S.K.; Hsiao, E.Y. Indigenous bacteria from the gut microbiota regulate host serotonin biosynthesis. Cell, 2015, 161(2), 264-276.
[http://dx.doi.org/10.1016/j.cell.2015.02.047] [PMID: 25860609]
[123]
Qin, H.Y.; Zang, K.H.; Zuo, X.; Wu, X.A.; Bian, Z.X. Quercetin attenuates visceral hypersensitivity and 5-Hydroxytryptamine availability in Postinflammatory irritable bowel syndrome rats: role of Enterochromaffin cells in the Colon. J. Med. Food, 2019, 22(7), 663-671.
[http://dx.doi.org/10.1089/jmf.2018.4264] [PMID: 30920336]
[124]
Andres, S.; Pevny, S.; Ziegenhagen, R.; Bakhiya, N.; Schäfer, B.; Hirsch-Ernst, K.I.; Lampen, A. Safety aspects of the use of quercetin as a dietary supplement. Mol. Nutr. Food Res., 2018, 62(1), 1700447.
[http://dx.doi.org/10.1002/mnfr.201700447] [PMID: 29127724]
[125]
Mohammadinejad, R.; Ahmadi, Z.; Tavakol, S.; Ashrafizadeh, M. Berberine as a potential autophagy modulator. J. Cell. Physiol., 2019, 234(9), 14914-14926.
[http://dx.doi.org/10.1002/jcp.28325] [PMID: 30770555]
[126]
Yu, Z.C.; Cen, Y.X.; Wu, B.H.; Wei, C.; Xiong, F.; Li, D.F.; Liu, T.T.; Luo, M.H.; Guo, L.L.; Li, Y.X.; Wang, L.S.; Wang, J.Y.; Yao, J. Berberine prevents stress-induced gut inflammation and visceral hypersensitivity and reduces intestinal motility in rats. World J. Gastroenterol., 2019, 25(29), 3956-3971.
[http://dx.doi.org/10.3748/wjg.v25.i29.3956] [PMID: 31413530]
[127]
Zhang, X.; Li, Z.; Leung, W.; Liu, L.; Xu, H.; Bian, Z. The analgesic effect of paeoniflorin on neonatal maternal separation-induced visceral hyperalgesia in rats. J. Pain, 2008, 9(6), 497-505.
[http://dx.doi.org/10.1016/j.jpain.2007.12.009] [PMID: 18387856]
[128]
Zhang, X.J.; Chen, H.L.; Li, Z.; Zhang, H.Q.; Xu, H.X.; Sung, J.J.Y.; Bian, Z.X. Analgesic effect of paeoniflorin in rats with neonatal maternal separation-induced visceral hyperalgesia is mediated through adenosine A1 receptor by inhibiting the extracellular signal-regulated protein kinase (ERK) pathway. Pharmacol. Biochem. Behav., 2009, 94(1), 88-97.
[http://dx.doi.org/10.1016/j.pbb.2009.07.013] [PMID: 19664651]
[129]
Chang, X.; Zhao, L.; Wang, J.; Lu, X.; Zhang, S. Sini-san improves duodenal tight junction integrity in a rat model of functional dyspepsia. BMC Complement. Altern. Med., 2017, 17(1), 432.
[http://dx.doi.org/10.1186/s12906-017-1938-2] [PMID: 28854971]
[130]
Cai, L.; Jiejie, L.; Hu, Y.; Chen, W.; Wei, L.; He, Q. A efficacy and safety of modified sini san for treating poststroke depression: A meta-analysis of randomized controlled trials. Explore (NY), 2020.
[PMID: 32527684]
[131]
Moussa, L.; Bézirard, V.; Salvador-Cartier, C.; Bacquié, V.; Houdeau, E.; Théodorou, V. A new soy germ fermented ingredient displays estrogenic and protease inhibitor activities able to prevent irritable bowel syndrome-like symptoms in stressed female rats. Clin. Nutr., 2013, 32(1), 51-58.
[http://dx.doi.org/10.1016/j.clnu.2012.05.021] [PMID: 22727545]
[132]
Lee, T.H.; Choi, J.J.; Kim, D.H.; Choi, S.; Lee, K.R.; Son, M.; Jin, M. Gastroprokinetic effects of DA-9701, a new prokinetic agent formulated with Pharbitis Semen and Corydalis Tuber. Phytomedicine, 2008, 15(10), 836-843.
[http://dx.doi.org/10.1016/j.phymed.2008.02.019] [PMID: 18490147]
[133]
Kim, E.R.; Min, B.H.; Lee, T.H.; Son, M.; Rhee, P.L. Effect of DA-9701 on colorectal distension-induced visceral hypersensitivity in a rat model. Gut Liver, 2014, 8(4), 388-393.
[http://dx.doi.org/10.5009/gnl.2014.8.4.388] [PMID: 25071903]
[134]
Lee, S.P.; Lee, K.N.; Lee, O.Y.; Lee, H.L.; Jun, D.W.; Yoon, B.C.; Choi, H.S.; Hwang, S.J.; Lee, S.E. Effects of DA-9701, a novel prokinetic agent, on phosphorylated extracellular signal-regulated kinase expression in the dorsal root ganglion and spinal cord induced by colorectal distension in rats. Gut Liver, 2014, 8(2), 140-147.
[http://dx.doi.org/10.5009/gnl.2014.8.2.140] [PMID: 24672654]
[135]
Gershon, M.D.; Tack, J. The serotonin signaling system: from basic understanding to drug development for functional GI disorders. Gastroenterology, 2007, 132(1), 397-414.
[http://dx.doi.org/10.1053/j.gastro.2006.11.002] [PMID: 17241888]
[136]
Madisch, A.; Melderis, H.; Mayr, G.; Sassin, I.; Hotz, J. A plant extract and its modified preparation in functional dyspepsia. Results of a double-blind placebo controlled comparative study Z. Gastroenterol., 2001, 39(7), 511-517.
[http://dx.doi.org/10.1055/s-2001-16142] [PMID: 11505331]
[137]
Müller, M.H.; Liu, C.Y.; Glatzle, J.; Weiser, D.; Kelber, O.; Enck, P.; Grundy, D.; Kreis, M.E. STW 5 (Iberogast®) reduces afferent sensitivity in the rat small intestine. Phytomedicine, 2006, 13(Suppl. 5), 100-106.
[http://dx.doi.org/10.1016/j.phymed.2006.03.014] [PMID: 16713220]
[138]
Malfertheiner, P. STW 5 (Iberogast) therapy in gastrointestinal functional disorders. Dig. Dis., 2017, 35(S1)(Suppl. 1), 25-29.
[http://dx.doi.org/10.1159/000485410] [PMID: 29421817]
[139]
Fan, H.; Qiu, M-Y.; Mei, J-J.; Shen, G-X.; Liu, S-L.; Chen, R. Effects of four regulating-intestine prescriptions on pathology and ultrastructure of colon tissue in rats with ulcerative colitis. World J. Gastroenterol., 2005, 11(31), 4800-4806.
[http://dx.doi.org/10.3748/wjg.v11.i31.4800] [PMID: 16097047]
[140]
Bian, Z.; Wu, T.; Liu, L.; Miao, J.; Wong, H.; Song, L.; Sung, J.J.Y. Effectiveness of the Chinese herbal formula TongXieYaoFang for irritable bowel syndrome: a systematic review. J. Altern. Complement. Med., 2006, 12(4), 401-407.
[http://dx.doi.org/10.1089/acm.2006.12.401] [PMID: 16722791]
[141]
Hu, X.G.; Xu, D.; Zhao, Y.; Yang, X.B.; Meng, J.; Shen, H.; Guo, J. The alleviating pain effect of aqueous extract from tong-xie-yao-fang, on experimental visceral hypersensitivity and its mechanism. Biol. Pharm. Bull., 2009, 32(6), 1075-1079.
[http://dx.doi.org/10.1248/bpb.32.1075] [PMID: 19483318]
[142]
Pan, F.; Zhang, T.; Zhang, Y.; Xu, J.; Chen, F. Effect of Tongxie Yaofang (痛泻要方) Granule in treating diarrhea-predominate irritable bowel syndrome. Chin. J. Integr. Med., 2009, 15(3), 216-219.
[http://dx.doi.org/10.1007/s11655-009-0216-7] [PMID: 19568715]
[143]
Yin, Y.; Zhong, L.; Wang, J.W.; Zhao, X.Y.; Zhao, W.J.; Kuang, H.X. Tong Xie Yao Fang relieves irritable bowel syndrome in rats via mechanisms involving regulation of 5-hydroxytryptamine and substance P. World J. Gastroenterol., 2015, 21(15), 4536-4546.
[http://dx.doi.org/10.3748/wjg.v21.i15.4536] [PMID: 25914462]
[144]
Bian, Z-X.; Zhang, M.; Han, Q-B.; Xu, H-X.; Sung, J.J. Analgesic effects of JCM-16021 on neonatal maternal separation-induced visceral pain in rats. World J. Gastroenterol., 2010, 16(7), 837-845.
[PMID: 20143462]
[145]
Huang, X; Zeng, B; Zhou, F; Wang, R; Zeng, H. Studies on Quality Standard for Kangtai Capsule. 2000(06). Trad Chin Drug Res Clinic Pharmacol, 2000, 6
[146]
Chen, Y.L.; Huang, X.Q.; Xu, S.J.; Liao, J.B.; Wang, R.J.; Lu, X.F.; Xie, Y.L.; Zhou, F.S.; Su, Z.R.; Lai, X.P. Relieving visceral hyperalgesia effect of Kangtai capsule and its potential mechanisms via modulating the 5-HT and NO level in vivo. Phytomedicine, 2013, 20(3-4), 249-257.
[http://dx.doi.org/10.1016/j.phymed.2012.09.027] [PMID: 23141427]
[147]
Mertz, H.; Naliboff, B.; Munakata, J.; Niazi, N.; Mayer, E.A. Altered rectal perception is a biological marker of patients with irritable bowel syndrome. Gastroenterology, 1995, 109(1), 40-52.
[http://dx.doi.org/10.1016/0016-5085(95)90267-8] [PMID: 7797041]
[148]
Rivkin, A. Tegaserod maleate in the treatment of irritable bowel syndrome: A clinical review. Clin. Ther., 2003, 25(7), 1952-1974.
[http://dx.doi.org/10.1016/S0149-2918(03)80198-4] [PMID: 12946544]
[149]
Sikander, A.; Rana, S.V.; Prasad, K.K. Role of serotonin in gastrointestinal motility and irritable bowel syndrome. Clin. Chim. Acta, 2009, 403(1-2), 47-55.
[http://dx.doi.org/10.1016/j.cca.2009.01.028] [PMID: 19361459]
[150]
Farmer, A.D.; Aziz, Q. Visceral pain hypersensitivity in functional gastrointestinal disorders. Br. Med. Bull., 2009, 91(1), 123-136.
[http://dx.doi.org/10.1093/bmb/ldp026] [PMID: 19620136]
[151]
Bortolotti, M.; Porta, S. Effect of red pepper on symptoms of irritable bowel syndrome: preliminary study. Dig. Dis. Sci., 2011, 56(11), 3288-3295.
[http://dx.doi.org/10.1007/s10620-011-1740-9] [PMID: 21573941]
[152]
Tatsuta, M.; Iishi, H. Effect of treatment with Liu-Jun-Zi-Tang (TJ-43) on gastric emptying and gastrointestinal symptoms in dyspeptic patients. Aliment. Pharmacol. Ther., 1993, 7(4), 459-462.
[http://dx.doi.org/10.1111/j.1365-2036.1993.tb00120.x] [PMID: 8218760]
[153]
Shiratori, M.; Shoji, T.; Kanazawa, M.; Hongo, M.; Fukudo, S. Effect of rikkunshito on gastric sensorimotor function under distention. Neurogastroenterol. Motil., 2011, 23(4), 323-e156.
[http://dx.doi.org/10.1111/j.1365-2982.2010.01648.x] [PMID: 21175995]
[154]
Liu, J.; Kou, F.; Tan, X.; Dai, Y.; Xie, C. Li, X Hewei Jiangni granule alleviates visceral hypersensitivity in a rat model of non-erosive reflux disease via transient receptor potential channel signaling. J Trad Chin Med Sci, 2020, 7(2), 162-170.
[http://dx.doi.org/10.1016/j.jtcms.2020.05.002]
[155]
Zhang, S.; Zhao, L.; Wang, H.; Wang, C.; Huang, S.; Shen, H.; Wei, W.; Tao, L.; Zhou, T. Efficacy of modified LiuJunZi decoction on functional dyspepsia of spleen-deficiency and qi-stagnation syndrome: A randomized controlled trial. BMC Complement. Altern. Med., 2013, 13(1), 54.
[http://dx.doi.org/10.1186/1472-6882-13-54] [PMID: 23453018]
[156]
Wang, X.; Wang, B.; Zhou, T. The study on the effects of Jianpi Liqi Decoction on rats with functional dyspepsia and its mechanism; Chin J Integr Tradition West Med Digest, 2012, pp. 297-300.
[157]
Bellono, N.W.; Bayrer, J.R.; Leitch, D.B.; Castro, J.; Zhang, C.; O’Donnell, T.A. Enterochromaffin cells are gut chemosensors that couple to sensory neural pathways. Cell, 2017, 170(1), 185-198.
[http://dx.doi.org/10.1016/j.cell.2017.05.034]
[158]
Zhao, J.; Zhao, L.; Zhang, S.; Zhu, C. Modified Liu-Jun-Zi decoction alleviates visceral hypersensitivity in functional dyspepsia by regulating EC cell-5HT3r signaling in duodenum. J. Ethnopharmacol., 2020, 250, 112468.
[http://dx.doi.org/10.1016/j.jep.2019.112468] [PMID: 31836517]
[159]
Moazzam, S.W.; Mobeen, A.; Siddiqui, M.A. Efficacy of Jawarish Shahi a herbal formulation in irritable bowel syndrome: An open-labeled single-arm clinical trial. J. Tradit. Complement. Med., 2022, 12(6), 529-535.
[http://dx.doi.org/10.1016/j.jtcme.2022.04.004] [PMID: 36325243]
[160]
Mobeen, A.; Moazzam, S.W. Jawarish Shahi: A special dosage form of herbal formulations for functional gastrointestinal disorders in Unani medicine- A comprehensive review. J. Ethnopharmacol., 2022, 293, 115319.
[http://dx.doi.org/10.1016/j.jep.2022.115319] [PMID: 35490900]

Rights & Permissions Print Cite
© 2025 Bentham Science Publishers | Privacy Policy